Results: There was no significant difference between QT end interval, JT interval and TDR at baseline and after implant with different pacing modes.
Methods:
The relationship between HRV and morbimortality was examined in a retrospective study concerning 34 patients who received CRT devices between july 2002 and february 2008. HRV footprint and standard deviation of averaged normal R to R intervals (SDANN) was continuously measured by devices.
Results:
The study showed an overall improvement in SDANN (71, 8 ± 18, 3 to 87, 6 ± 29 ms, p=0, 002) and HRV footprint (33,5 ± 9,2 to 37,5 ± 9%, p=0,013) after resynchronization. During a median of 17,7 months of follow up, 26% (9/34) patients died or were hospitalised for acute heart failure. SDANN and HRV foorprint at the time of device implantation were not predictors of morbimortality. Improvement of SDANN > 5% after resynchronization was predictor of survival free from event (p<0,0001). Background: Radiofrequency (RF) isolation of pulmonary veins (PVs) has emerged as an effective treatment for patients presenting drug refractory atrial fibrillation (AF). The objective of this study was to assess the feasibility, safety, and short-term outcome of pulmonary vein isolation (PVI) in paroxysmal and persistent AF patients with a new cryoballoon catheter technique (Arctic Front, Cryocath, Quebec, Canada).
Conclusion

Methods:
Between December 2007 and April 2009, 37 patients (25 males, mean age 56 years old) with symptomatic, drug refractory, paroxysmal (n= 36) or persistent (n= 1) AF underwent circumferential antral PVI using a double lumen 23 or 28 mm cryoballoon catheter. Before discharge, all patients were subjected to 24-hour Holter electrocardiograms, echocardiography, and esophageal endoscopy. In case of symptomatic recurrences, a second AF ablation aiming at PV isolation, was performed using RF catheter.
Results: Out of 148 treated veins, 140 were completely isolated (94.6 %). All PVs were completely isolated in 28/37 patients (75.6 %). The number of balloon applications per vein was 2.18 ± 0.69. The mean procedure and fluoroscopy time were 164.8 ± 39.3 and 32.4 ± 12.3 min respectively. Thirty-one patients were free of AF at hospital discharge (83.8 %). No PV narrowing, atrio-esophageal fistula or thromboembolic event occurred. Three phrenic nerve palsy (8.1%) were observed after cryoapplication at the right superior PV. Two of them resolved immediately after cessation of cryoenergy, one resolved at 2 weeks. The most frequent complications were pericardial effusions (n=8) and groin hematoma (n= 3) or ecchymosis (n=6), all spontaneously reversible. Among the 15 patients seen at 4 months follow-up, all were AF free after one (n = 11) or two procedures (n= 4) without any antiarythmic drugs.
Conclusion:
Cryoballoon PVI appears as an effective and safe technique with a relatively high clinical success rate at short-term follow-up. Methods: All pts diagnosed with BS at Bordeaux CHU between 1999 and 2009 have been enrolled in a prospective registry. All patients with syncope were enrolled in the present study (Group 1 without and Group 2 with a "clear extracardiac cause" of syncope). Patients were followed in the clinic or by phone annually unless there was an event.
Results: Of 185 pts with BS, 49 (39 male, 47 ±12yo) had at least one syncope. All 27 pts in group 1 received an ICD. Of the 22 pts in group 2, 4 received an implantable loop recorder [MJW1] (ILR) and 1 patient received an ICD after positive EP study.
With a mean follow-up of 53 ±38 months, 19 pts were asymptomatic, 5 had appropriate ICD therapy, 2 patients had further syncopal events not associated with cardiac arrhythmia and 1 pt died of a non cardiac cause in group 1. In group 2, 14pts were asymptomatic, 5 had recurrent atypical syncopal events (without arrhythmia shown by ILR in 3 pts), 2 experienced atypical chest pain and 1 died of drug abuse. 
Conclusions
